Shares of ICU Medical (NASDAQ:ICUI) have been assigned an average rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $266.00.

Several equities research analysts have commented on the stock. BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 7th. Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $266.00 price objective for the company in a research note on Tuesday, January 23rd.

How to Become a New Pot Stock Millionaire

ICU Medical stock traded down $0.30 during trading hours on Friday, reaching $252.60. 151,538 shares of the company’s stock traded hands, compared to its average volume of 138,661. The stock has a market cap of $5,032.54, a price-to-earnings ratio of 76.29, a price-to-earnings-growth ratio of 2.50 and a beta of 0.42. ICU Medical has a 52-week low of $144.25 and a 52-week high of $265.27.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, March 1st. The medical instruments supplier reported $2.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $1.94. The firm had revenue of $370.12 million during the quarter, compared to analyst estimates of $332.91 million. ICU Medical had a net margin of 5.31% and a return on equity of 8.42%. The company’s revenue for the quarter was up 286.8% on a year-over-year basis. During the same quarter last year, the business posted $1.20 EPS. equities research analysts expect that ICU Medical will post 6.29 earnings per share for the current year.

In other news, Director Robert S. Swinney sold 724 shares of the stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $235.00, for a total transaction of $170,140.00. Following the completion of the transaction, the director now directly owns 14,830 shares of the company’s stock, valued at approximately $3,485,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott E. Lamb sold 23,624 shares of the stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $220.00, for a total transaction of $5,197,280.00. Following the transaction, the chief financial officer now directly owns 29,723 shares of the company’s stock, valued at $6,539,060. The disclosure for this sale can be found here. In the last quarter, insiders sold 45,431 shares of company stock valued at $10,662,861. Company insiders own 13.60% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in ICUI. Exane Derivatives bought a new position in shares of ICU Medical during the 4th quarter valued at approximately $100,000. Israel Discount Bank of New York boosted its holdings in ICU Medical by 74.8% in the 4th quarter. Israel Discount Bank of New York now owns 853 shares of the medical instruments supplier’s stock worth $184,000 after buying an additional 365 shares during the period. Eagle Boston Investment Management Inc. bought a new position in ICU Medical in the 3rd quarter worth approximately $200,000. First Republic Investment Management Inc. bought a new position in ICU Medical in the 4th quarter worth approximately $200,000. Finally, Raymond James Trust N.A. bought a new position in ICU Medical in the 4th quarter worth approximately $204,000. 77.30% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “ICU Medical (ICUI) Receives Consensus Recommendation of “Buy” from Brokerages” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/icu-medical-icui-receives-consensus-recommendation-of-buy-from-brokerages/1954479.html.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein for use in hospitals and ambulatory clinics.

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.